Seselin|cas:523-59-1|西域试剂

Seselin

产品编号：Bellancom-W505771| CAS NO：523-59-1| 分子式：C₁₄H₁₂O₃| 分子量：228.24

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-W505771		￥1500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Seselin

产品介绍

Seselin 是一种抗癌、抗炎、抗真菌剂，具有口服活性。

生物活性

Seselin is an anticancer, antinociceptive, anti-inflammatory and antifungal agent. Seselin is orally active.

体外研究

Seselin 对 P-388 和 HT-29 细胞有毒性，ED₅₀ 分别为 8.66 和 9.94 μg/mL 。
Seselin (5-20 μM; 0.5-24 h) 抑制 LPS 和 IFN-γ 刺激的巨噬细胞的细胞因子输出。
Seselin (5-20 μM; 12 h) 抑制 BMDMs 中促炎巨噬细胞标志物 (iNOS、phagocytosis、CD11c) 的表达。
Seselin (5-20 μM; 0.5-6 h) 阻断 STAT1 信号通路。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR

Cell Line:	Bone marrow-derived macrophages (BMDMs)
Concentration:	5, 10 and 20 μM
Incubation Time:	6 h
Result:	Reduced the mRNA for cytokines (IL-1β, IL-6, Tnf-α and IL-23) and chemokines (Ccl3, Ccl7, Cxcl9 and Cxcl11) concentration-dependently in BMDMs.

Western Blot Analysis

Cell Line:	BMDMs
Concentration:	5, 10 and 20 μM
Incubation Time:	0.5, 1.5, 3 and 6 h
Result:	Suppressed expression of p-STAT1 and p-p65 both concentration and time dependently.

体内研究
(In Vivo)

Seselin (0.5-40.5 mg/kg; s.c.; once) 在小鼠中显示外周抗炎和抗伤感受活性。
Seselin (3-30 mg/kg; i.g.; once) 改善小鼠盲肠结扎和穿刺引起的脓毒症。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Swiss mice
Dosage:	0.5, 4.5 or 40.5 mg/kg
Administration:	Subcutaneous injection; once
Result:	Inhibited the writhing response induced by acetic acid in a significant and dose-dependent manner, by 19.5%, 26.2% and 41.4% at dose of 0.5, 4.5 or 40.5 mg/kg, respectively. Elicited a significant inhibition of formalin response during the second phase (inflammatory), by 90.3%, 97.8% and 95.3%, respectively.

Animal Model:	C57BL/6 mice, caecal ligation and puncture (CLP) induced sepsis model
Dosage:	3, 10 and 30 mg/kg
Administration:	Intragastric administration, once
Result:	Ameliorated lung injury and decreased JAK2 phosphorylation level in lung tissue during sepsis. Reduced the immune cell counts in BALF induced by CLP.

体内研究

Seselin (0.5-40.5 mg/kg; s.c.; once) 在小鼠中显示外周抗炎和抗伤感受活性。
Seselin (3-30 mg/kg; i.g.; once) 改善小鼠盲肠结扎和穿刺引起的脓毒症。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Swiss mice
Dosage:	0.5, 4.5 or 40.5 mg/kg
Administration:	Subcutaneous injection; once
Result:	Inhibited the writhing response induced by acetic acid in a significant and dose-dependent manner, by 19.5%, 26.2% and 41.4% at dose of 0.5, 4.5 or 40.5 mg/kg, respectively. Elicited a significant inhibition of formalin response during the second phase (inflammatory), by 90.3%, 97.8% and 95.3%, respectively.

Animal Model:	C57BL/6 mice, caecal ligation and puncture (CLP) induced sepsis model
Dosage:	3, 10 and 30 mg/kg
Administration:	Intragastric administration, once
Result:	Ameliorated lung injury and decreased JAK2 phosphorylation level in lung tissue during sepsis. Reduced the immune cell counts in BALF induced by CLP.

体内研究

Seselin (0.5-40.5 mg/kg; s.c.; once) 在小鼠中显示外周抗炎和抗伤感受活性。
Seselin (3-30 mg/kg; i.g.; once) 改善小鼠盲肠结扎和穿刺引起的脓毒症。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Swiss mice
Dosage:	0.5, 4.5 or 40.5 mg/kg
Administration:	Subcutaneous injection; once
Result:	Inhibited the writhing response induced by acetic acid in a significant and dose-dependent manner, by 19.5%, 26.2% and 41.4% at dose of 0.5, 4.5 or 40.5 mg/kg, respectively. Elicited a significant inhibition of formalin response during the second phase (inflammatory), by 90.3%, 97.8% and 95.3%, respectively.

Animal Model:	C57BL/6 mice, caecal ligation and puncture (CLP) induced sepsis model
Dosage:	3, 10 and 30 mg/kg
Administration:	Intragastric administration, once
Result:	Ameliorated lung injury and decreased JAK2 phosphorylation level in lung tissue during sepsis. Reduced the immune cell counts in BALF induced by CLP.